Abstract: A method of providing a subject polypeptide variant with improved stability compared with a parent subject polypeptide, employing translation and selection using an RNA expression system, wherein two or more stability selection pressures are applied simultaneously during translation, two or more stability selection pressures are applied simultaneously during selecting, or at least one stability selection pressure is applied during translation and continues to be applied during selecting, and at least one further stability selection pressure is applied during selecting.

Abstract: The present invention provides clustered ligand vehicles for the delivery of a nucleic acid therapeutic agent to a target expressing a receptor. The invention further provides methods for treating a disease state by targeting a nucleic acid therapeutic agent to a target expressing a receptor using clustered ligand vehicles.

Abstract: The present invention concerns the use of a sphingoid-polyalkylamine conjugate comprising a sphingoid backbone carrying, via a carbamoyl bond, at least one polyalkylamine chains as a capturing agent of nucleic acid molecules. The present invention also provides the use of the sphingoid polyalkylamine conjugate for the preparation of a pharmaceutical composition for the delivery of a nucleic acid molecule into a target cell. In a further aspect the invention provides a method for transfecting a nucleic acid into a target cell, the method comprises contacting said target cell with the sphingoid-polyalkylamine conjugate associated with a nucleic acid molecule, thereby transfecting said target cell with said nucleic acid molecule. Other aspects of the invention concern pharmaceutical compositions comprising said conjugate, therapeutic methods as well as kits, making use of the said conjugate. A preferred conjugate according to the invention is N-palmitoyl D-erythrosphingosyl-1-carbamoyl spermine.

Abstract: Herbicide combinations comprising an effective amount of components (A) and (B), where component (A) is one or more herbicides of the formula (I) or salts thereof, in which R1 is H or a group of the formula CZ1Z2Z3, where Z1, Z2 and Z3 are as defined in claim 1, R2 and R3 are each H, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl having in each case up to 4 carbon atoms or acyl, R4 is H, (C1-C6)-alkyl or (C1-C6)-alkoxy; R5, R6, R7 and R8 are each H, (C1-C4)-alkyl, (C1-C3)-haloalkyl, halogen, (C1-C3)-alkoxy, (C1-C3)-haloalkoxy or cyano; A is CH2 or O or a direct bond, and component (B) is one or more herbicides from the group of compounds consisting of (B1) soil-acting herbicides particularly suitable for pre-emergence application against monocotyledonous or dicotyledonous harmful plants, (B2) foliar-acting herbicides particularly suitable for post-emergence application against monocotyledonous or dicotyledonous harmful plants, and (B3) soil-acting and foliar-acting herbicides suitable fo

Abstract: A DNA sequence encoding a protein capable of binding to a tumor necrosis factor receptor-associated factor (TRAF) molecule, TRAF-binding proteins, their isoforms, analogs, fragments and derivatives encoded by the DNA sequence, their methods for the production of the DNA sequences and proteins, and the uses for the DNA sequence and proteins.

Abstract: A short synthetic vector peptide of 25 residues has been developed comprising hydrophobic domain and a novel, nuclear localization signal for efficient delivery, devoid of any cytotoxicity. Using the vector peptide, the oligonucleotide/peptide complexes got delivered evenly in cytoplasm and nucleus in less than an hour and finally localizing completely into nucleus in two hours and protein (antibody) to cytoplasm within 1 hour in both primary (chicken embryo fibroblast) cells and established mammalian cell line (Vero cells).

Abstract: The present invention relates to novel oligonucleotide chimera used as therapeutic agents to selectively prevent gene transcription and expression in a sequence-specific manner. In particular, this invention is directed to the selective inhibition of protein biosynthesis via antisense strategy using oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length. Particularly this invention relates to the use of antisense oligonucleotides constructed from arabinonucleotide or modified arabinonucleotide residues, flanking a series of deoxyribose nucleotide residues of variable length, to hybridize to complementary RNA such as cellular messenger RNA, viral RNA, etc.

Abstract: The present disclosure concerns LNA oligonucleotides having a (sub)sequence of the general formula 5?-(MeCx)(Tx)MeCxAsAstscscsastsgsgsMeCxAx(Gx)(c)-3?, and preferably of the general formula 5?-MeCxTxMeCxAsastscscsastsgsgsMeCxAxGxc-3?, wherein capital letters designate an LNA nucleotide analogue selected from ?-D-oxy-LNA, ?-D-thio-LNA, ?-D-amino-LNA and ?-L-oxy-LNA, small letters designate a deoxynucleotide, and underline designates either an LNA nucleotide analogue as defined above or a deoxynucleotide. Such LNA oligonucleotides exhibit surprisingly good properties with respect to inhibition of the expression of Survivin by means of an anti-sense mechanism, and thereby lead to reduction or inhibition of tumor development in vivo.

Abstract: A method for modulating RNA with tetracycline compounds is described.

Abstract: The present invention relates to a herbicide combination comprising components (A) and (B) where (A) denotes one or more compounds or salts thereof from the group described by the general formula (I): in which R1 is halogen, preferably fluorine or chlorine, R2 is hydrogen and R3 is hydroxyl or R2 and R3 together with the carbon atom to which they are attached are a carbonyl group C?O and R4 is hydrogen or methyl; and (B) denotes one or more herbicides from the group of the pyrimidines consisting of: (B1-1) ancymidol, (B1-2) flurprimidol, (B1-3) pyrimisulfan, (B2-1) bispyribac-sodium, (B2-2) pyribenzoxim, (B2-3) pyriminobac-methyl, (B2-4) pyribambenz-isopropyl, (B2-5) pyribambenz-propyl, (B3-1) pyriftalid, (B3-2) pyrithiobac-sodium, (B4-1) benzfendizone, (B4-2) bromacil, (B4-3) butafenacil, (B4-4) lenacil, (B4-5) terbacil, (B4-6) SYN-523, (B4-7) saflufenacil.

Abstract: The invention provides a physiologically active polypeptide- or protein-encapsulating polymer micelle composition derived from a block copolymer comprising hydrophilic segments and hydrophobic segments.

Abstract: A dosage cap assembly is provided for use with an applicator assembly, the dosage cap assembly including a tip including an outer surface, an attachment end, a second end, and an inner surface defining a tip cavity, wherein the attachment end of the tip includes an engagement mechanism. The dosage cap assembly also includes a cap having an inner surface defining a cap cavity, the inner surface generally conforming to the outer surface of the tip; and a dosage form disposed within the tip cavity.

Abstract: The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.

Abstract: The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.

Abstract: The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.

Abstract: The present invention is directed to eubacterial tmDNA sequences and the corresponding tmRNA sequences. The present invention is further directed to alignments of eubacterial tmDNA sequences and the use of the sequences and sequence alignments for the development of antibacterial drugs. The present invention is also directed to the use of the sequences for the development of diagnostic assays.

Abstract: Compounds, compositions and methods are provided for modulating the expression of growth hormone receptor and/or insulin like growth factor-I (IGF-I). The compositions comprise oligonucleotides, targeted to nucleic acid encoding growth hormone receptor. Methods of using these compounds for modulation of growth hormone receptor expression and for diagnosis and treatment of disease associated with expression of growth hormone receptor and/or insulin-like growth factor-I are provided. Diagnostic methods and kits are also provided.

Abstract: The present invention relates to methods and compositions for the inhibition of gene expression. In particular, the present invention provides oligonucleotide-based therapeutics for the inhibition of oncogenes involved in cancers.

Abstract: The present invention provides compositions comprising polytheylyene-dialkyloxypropyl conjugates (PEG-DAA), liposomes, SNALP, and SPLP comprising such compositions, and methods of using such compositions, liposomes, SNALP, and SPLP.

Abstract: ?v?3 Integrin receptor targeting liposomes comprise a cationic amphiphile such as a cationic lipid, a neutral lipid, and a targeting lipid. The targeting lipid includes a non-peptidic ?v?3 integrin antagonist.